Sangamo Executives Stick to RSU Vesting, No Market Sell-Offs—Shareholders See Commitment, Not Confidence Worry
Insightful insider RSU sales at Sangamo Therapeutics show top execs are staying invested, not liquidating—signaling confidence in its genetic‑therapy pipeline for long‑term investors.
4 minutes to read